{"title":"通过主动脉收缩进行远程预适应:它是否提供类似于经典或其他远程缺血预适应的心脏保护?诱导型一氧化氮合酶的作用","authors":"Ashish Kumar Sharma , Arshee Munajjam , Bhawna Vaishnav , Richa Sharma , Kunal Kishore , Ashok Sharma , Akash Sharma , Divya Sharma , Rita Kumari , Ashish Tiwari , B.P. Srinivasan , Shyam Sunder Agarwal","doi":"10.1016/j.cvdpc.2010.12.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose of the research</h3><p>Does remote preconditioning by aortic constriction (RPAC) afford cardioprotection similar to classical or other remote ischaemic preconditioning stimulus? Moreover, the study was also designed to investigate the role of inducible nitric oxide synthase (iNOS) in remote preconditioning by aortic constriction. There are sufficient evidence that ‘ischaemic preconditioning’ has surgical applications and affords clinically relevant cardioprotection. Transient occlusion of the circumflex artery, renal artery, limb artery or mesenteric artery preconditions the myocardium against ischaemia/reperfusion injury in case of ischaemic heart disease leading to myocardial infarction. Here, the abdominal aorta was selected to produce RPAC.</p></div><div><h3>The principal results</h3><p>Four episodes of ischaemia/reperfusion of 5<!--> <!-->min each to the abdominal aorta produced RPAC by assessment of infarct size, lactate dehydrogenase (LDH) and creatine phosphokinase (CK). These studies suggest RPAC produced acute (FWOP) and delayed (SWOP) cardioprotective effects. RPAC demonstrated a significant decrease in ischaemia/reperfusion-induced release of LDH, CK and extent of myocardial infarct size. <span>l</span>-NAME (nitro-<span>l</span>-arginine-methylester) (10<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.), aminoguanidine (150<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> s.c.), aminoguanidine (300<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> s.c.), S-methyl isothiourea (3<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.) and 1400W (1<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.) administered 10<!--> <!-->min. before global ischaemia/reperfusion produced no marked effect. Aminoguanidine (150<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> s.c.), aminoguanidine (300<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> s.c.), S-methyl isothiourea (3<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.) and 1400W (1<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.) pre-treatment after RPAC produced no significant effect on acute RPAC-induced decrease in LDH, CK and infarct size, whereas <span>l</span>-NAME (10<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.) increased RPAC-induced decrease in LDH, CK and infarct size. The most interesting observation is with respect to delayed RPAC, where all NOS inhibitors’ pre-treatment attenuate RPAC-induced decrease in LDH, CK and infarct size.</p></div><div><h3>Major conclusions</h3><p>RPAC affords cardioprotection similar to classical or other remote ischaemic preconditioning stimulus. Moreover, late or delayed phase of RPAC has been mediated iNOS, whereas it is not involved in acute RPAC.</p></div>","PeriodicalId":11021,"journal":{"name":"Cvd Prevention and Control","volume":"6 1","pages":"Pages 15-33"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cvdpc.2010.12.001","citationCount":"1","resultStr":"{\"title\":\"Remote preconditioning by aortic constriction: Does it afford cardioprotection similar to classical or other remote ischaemic preconditioning? Role of inducible nitric oxide synthase\",\"authors\":\"Ashish Kumar Sharma , Arshee Munajjam , Bhawna Vaishnav , Richa Sharma , Kunal Kishore , Ashok Sharma , Akash Sharma , Divya Sharma , Rita Kumari , Ashish Tiwari , B.P. Srinivasan , Shyam Sunder Agarwal\",\"doi\":\"10.1016/j.cvdpc.2010.12.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose of the research</h3><p>Does remote preconditioning by aortic constriction (RPAC) afford cardioprotection similar to classical or other remote ischaemic preconditioning stimulus? Moreover, the study was also designed to investigate the role of inducible nitric oxide synthase (iNOS) in remote preconditioning by aortic constriction. There are sufficient evidence that ‘ischaemic preconditioning’ has surgical applications and affords clinically relevant cardioprotection. Transient occlusion of the circumflex artery, renal artery, limb artery or mesenteric artery preconditions the myocardium against ischaemia/reperfusion injury in case of ischaemic heart disease leading to myocardial infarction. Here, the abdominal aorta was selected to produce RPAC.</p></div><div><h3>The principal results</h3><p>Four episodes of ischaemia/reperfusion of 5<!--> <!-->min each to the abdominal aorta produced RPAC by assessment of infarct size, lactate dehydrogenase (LDH) and creatine phosphokinase (CK). These studies suggest RPAC produced acute (FWOP) and delayed (SWOP) cardioprotective effects. RPAC demonstrated a significant decrease in ischaemia/reperfusion-induced release of LDH, CK and extent of myocardial infarct size. <span>l</span>-NAME (nitro-<span>l</span>-arginine-methylester) (10<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.), aminoguanidine (150<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> s.c.), aminoguanidine (300<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> s.c.), S-methyl isothiourea (3<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.) and 1400W (1<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.) administered 10<!--> <!-->min. before global ischaemia/reperfusion produced no marked effect. Aminoguanidine (150<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> s.c.), aminoguanidine (300<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> s.c.), S-methyl isothiourea (3<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.) and 1400W (1<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.) pre-treatment after RPAC produced no significant effect on acute RPAC-induced decrease in LDH, CK and infarct size, whereas <span>l</span>-NAME (10<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.) increased RPAC-induced decrease in LDH, CK and infarct size. The most interesting observation is with respect to delayed RPAC, where all NOS inhibitors’ pre-treatment attenuate RPAC-induced decrease in LDH, CK and infarct size.</p></div><div><h3>Major conclusions</h3><p>RPAC affords cardioprotection similar to classical or other remote ischaemic preconditioning stimulus. Moreover, late or delayed phase of RPAC has been mediated iNOS, whereas it is not involved in acute RPAC.</p></div>\",\"PeriodicalId\":11021,\"journal\":{\"name\":\"Cvd Prevention and Control\",\"volume\":\"6 1\",\"pages\":\"Pages 15-33\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.cvdpc.2010.12.001\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cvd Prevention and Control\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1875457011000027\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cvd Prevention and Control","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1875457011000027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
研究目的:通过主动脉收缩(RPAC)进行的远程预适应是否提供与经典或其他远程缺血预适应刺激相似的心脏保护?此外,本研究还旨在探讨诱导型一氧化氮合酶(iNOS)在主动脉收缩远程预适应中的作用。有足够的证据表明,“缺血预处理”有外科应用,并提供临床相关的心脏保护。在缺血性心脏病导致心肌梗死的情况下,旋动脉、肾动脉、肢体动脉或肠系膜动脉的短暂闭塞为心肌抗缺血/再灌注损伤提供了先决条件。在这里,选择腹主动脉产生RPAC。主要结果:通过评估梗死面积、乳酸脱氢酶(LDH)和肌酸磷酸激酶(CK),腹腔主动脉缺血/再灌注4次,每次5分钟产生RPAC。这些研究表明RPAC具有急性(FWOP)和延迟(SWOP)心脏保护作用。RPAC可显著降低缺血/再灌注诱导的LDH、CK释放和心肌梗死面积。在全脑缺血/再灌注前10分钟给予l-NAME(硝基-l-精氨酸-甲基lester) (10mg kg - 1静脉注射)、氨基胍(150mg kg - 1静脉注射)、氨基胍(300mg kg - 1静脉注射)、s -甲基异硫脲(3mg kg - 1静脉注射)和1400W (1mg kg - 1静脉注射),均未产生显著效果。RPAC后预处理氨基胍(150 mg kg−1 s.c.)、氨基胍(300 mg kg−1 s.c.)、s -甲基异硫脲(3 mg kg−1 I.V.)和1400W (1 mg kg−1 I.V.)对RPAC诱导的LDH、CK和梗死面积的急性降低没有显著影响,而l-NAME (10 mg kg−1 I.V.)增加了RPAC诱导的LDH、CK和梗死面积的降低。最有趣的观察结果是关于延迟RPAC,其中所有NOS抑制剂的预处理都减弱了RPAC诱导的LDH, CK和梗死面积的降低。主要结论:srpac具有与经典或其他远端缺血预处理刺激相似的心脏保护作用。此外,RPAC晚期或延迟期已介导iNOS,而它不参与急性RPAC。
Remote preconditioning by aortic constriction: Does it afford cardioprotection similar to classical or other remote ischaemic preconditioning? Role of inducible nitric oxide synthase
Purpose of the research
Does remote preconditioning by aortic constriction (RPAC) afford cardioprotection similar to classical or other remote ischaemic preconditioning stimulus? Moreover, the study was also designed to investigate the role of inducible nitric oxide synthase (iNOS) in remote preconditioning by aortic constriction. There are sufficient evidence that ‘ischaemic preconditioning’ has surgical applications and affords clinically relevant cardioprotection. Transient occlusion of the circumflex artery, renal artery, limb artery or mesenteric artery preconditions the myocardium against ischaemia/reperfusion injury in case of ischaemic heart disease leading to myocardial infarction. Here, the abdominal aorta was selected to produce RPAC.
The principal results
Four episodes of ischaemia/reperfusion of 5 min each to the abdominal aorta produced RPAC by assessment of infarct size, lactate dehydrogenase (LDH) and creatine phosphokinase (CK). These studies suggest RPAC produced acute (FWOP) and delayed (SWOP) cardioprotective effects. RPAC demonstrated a significant decrease in ischaemia/reperfusion-induced release of LDH, CK and extent of myocardial infarct size. l-NAME (nitro-l-arginine-methylester) (10 mg kg−1 I.V.), aminoguanidine (150 mg kg−1 s.c.), aminoguanidine (300 mg kg−1 s.c.), S-methyl isothiourea (3 mg kg−1 I.V.) and 1400W (1 mg kg−1 I.V.) administered 10 min. before global ischaemia/reperfusion produced no marked effect. Aminoguanidine (150 mg kg−1 s.c.), aminoguanidine (300 mg kg−1 s.c.), S-methyl isothiourea (3 mg kg−1 I.V.) and 1400W (1 mg kg−1 I.V.) pre-treatment after RPAC produced no significant effect on acute RPAC-induced decrease in LDH, CK and infarct size, whereas l-NAME (10 mg kg−1 I.V.) increased RPAC-induced decrease in LDH, CK and infarct size. The most interesting observation is with respect to delayed RPAC, where all NOS inhibitors’ pre-treatment attenuate RPAC-induced decrease in LDH, CK and infarct size.
Major conclusions
RPAC affords cardioprotection similar to classical or other remote ischaemic preconditioning stimulus. Moreover, late or delayed phase of RPAC has been mediated iNOS, whereas it is not involved in acute RPAC.